2019
Boudny, Miroslav; Zemanova, Jana; Khirsariya, Prashant; Borsky, Marek; Verner, Jan; Cerna, Jana; Oltova, Alexandra; Seda, Vaclav; Mraz, Marek; Jaros, Josef; Jaskova, Zuzana; Spunarova, Michaela; Brychtova, Yvona; Soucek, Karel; Drapela, Stanislav; Kasparkova, Marie; Mayer, Jiri; Paruch, Kamil; Trbusek, Martin
Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells. Journal Article
In: Haematologica, vol. 104, no. 12, pp. 2443–2455, 2019, ISSN: 1592-8721 0390-6078, (Place: Italy).
Abstract | Links | BibTeX | Tags: *Drug Synergism, *Mutation, Animals, Antimetabolites, Antineoplastic/pharmacology, Apoptosis, B-Cell/*drug therapy/genetics/pathology, Biomarkers, Cell Cycle, Cell Proliferation, Checkpoint Kinase 1/*antagonists & inhibitors, Chronic, Cultured, Deoxycytidine/analogs & derivatives/pharmacology, Drug resistance, Female, gemcitabine, Gene Expression Regulation, Humans, Inbred NOD, Leukemia, Lymphocytic, Mice, Neoplasm/drug effects, Neoplastic/*drug effects, Piperidines/*pharmacology, Protein Kinase Inhibitors/pharmacology, Pyrazoles/*pharmacology, Pyrimidines/*pharmacology, SCID, Tumor Cells, Tumor Suppressor Protein p53/*genetics, Tumor/genetics, Xenograft Model Antitumor Assays
@article{boudny_novel_2019,
title = {Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells.},
author = {Miroslav Boudny and Jana Zemanova and Prashant Khirsariya and Marek Borsky and Jan Verner and Jana Cerna and Alexandra Oltova and Vaclav Seda and Marek Mraz and Josef Jaros and Zuzana Jaskova and Michaela Spunarova and Yvona Brychtova and Karel Soucek and Stanislav Drapela and Marie Kasparkova and Jiri Mayer and Kamil Paruch and Martin Trbusek},
doi = {10.3324/haematol.2018.203430},
issn = {1592-8721 0390-6078},
year = {2019},
date = {2019-12-01},
journal = {Haematologica},
volume = {104},
number = {12},
pages = {2443–2455},
abstract = {Introduction of small-molecule inhibitors of B-cell receptor signaling and BCL2 protein significantly improves therapeutic options in chronic lymphocytic leukemia. However, some patients suffer from adverse effects mandating treatment discontinuation, and cases with TP53 defects more frequently experience early progression of the disease. Development of alternative therapeutic approaches is, therefore, of critical importance. Here we report details of the anti-chronic lymphocytic leukemia single-agent activity of MU380, our recently identified potent, selective, and metabolically robust inhibitor of checkpoint kinase 1. We also describe a newly developed enantioselective synthesis of MU380, which allows preparation of gram quantities of the substance. Checkpoint kinase 1 is a master regulator of replication operating primarily in intra-S and G(2)/M cell cycle checkpoints. Initially tested in leukemia and lymphoma cell lines, MU380 significantly potentiated efficacy of gemcitabine, a clinically used inducer of replication stress. Moreover, MU380 manifested substantial single-agent activity in both TP53-wild type and TP53-mutated leukemia and lymphoma cell lines. In chronic lymphocytic leukemia-derived cell lines MEC-1, MEC-2 (both TP53-mut), and OSU-CLL (TP53-wt) the inhibitor impaired cell cycle progression and induced apoptosis. In primary clinical samples, MU380 used as a single-agent noticeably reduced the viability of unstimulated chronic lymphocytic leukemia cells as well as those induced to proliferate by anti-CD40/IL-4 stimuli. In both cases, effects were comparable in samples harboring p53 pathway dysfunction (TP53 mutations or ATM mutations) and TP53-wt/ATM-wt cells. Lastly, MU380 also exhibited significant in vivo activity in a xenotransplant mouse model (immunodeficient strain NOD-scid IL2Rγ(null) ) where it efficiently suppressed growth of subcutaneous tumors generated from MEC-1 cells.},
note = {Place: Italy},
keywords = {*Drug Synergism, *Mutation, Animals, Antimetabolites, Antineoplastic/pharmacology, Apoptosis, B-Cell/*drug therapy/genetics/pathology, Biomarkers, Cell Cycle, Cell Proliferation, Checkpoint Kinase 1/*antagonists & inhibitors, Chronic, Cultured, Deoxycytidine/analogs & derivatives/pharmacology, Drug resistance, Female, gemcitabine, Gene Expression Regulation, Humans, Inbred NOD, Leukemia, Lymphocytic, Mice, Neoplasm/drug effects, Neoplastic/*drug effects, Piperidines/*pharmacology, Protein Kinase Inhibitors/pharmacology, Pyrazoles/*pharmacology, Pyrimidines/*pharmacology, SCID, Tumor Cells, Tumor Suppressor Protein p53/*genetics, Tumor/genetics, Xenograft Model Antitumor Assays},
pubstate = {published},
tppubtype = {article}
}
Introduction of small-molecule inhibitors of B-cell receptor signaling and BCL2 protein significantly improves therapeutic options in chronic lymphocytic leukemia. However, some patients suffer from adverse effects mandating treatment discontinuation, and cases with TP53 defects more frequently experience early progression of the disease. Development of alternative therapeutic approaches is, therefore, of critical importance. Here we report details of the anti-chronic lymphocytic leukemia single-agent activity of MU380, our recently identified potent, selective, and metabolically robust inhibitor of checkpoint kinase 1. We also describe a newly developed enantioselective synthesis of MU380, which allows preparation of gram quantities of the substance. Checkpoint kinase 1 is a master regulator of replication operating primarily in intra-S and G(2)/M cell cycle checkpoints. Initially tested in leukemia and lymphoma cell lines, MU380 significantly potentiated efficacy of gemcitabine, a clinically used inducer of replication stress. Moreover, MU380 manifested substantial single-agent activity in both TP53-wild type and TP53-mutated leukemia and lymphoma cell lines. In chronic lymphocytic leukemia-derived cell lines MEC-1, MEC-2 (both TP53-mut), and OSU-CLL (TP53-wt) the inhibitor impaired cell cycle progression and induced apoptosis. In primary clinical samples, MU380 used as a single-agent noticeably reduced the viability of unstimulated chronic lymphocytic leukemia cells as well as those induced to proliferate by anti-CD40/IL-4 stimuli. In both cases, effects were comparable in samples harboring p53 pathway dysfunction (TP53 mutations or ATM mutations) and TP53-wt/ATM-wt cells. Lastly, MU380 also exhibited significant in vivo activity in a xenotransplant mouse model (immunodeficient strain NOD-scid IL2Rγ(null) ) where it efficiently suppressed growth of subcutaneous tumors generated from MEC-1 cells.
2017
Herůdková, Jarmila; Paruch, Kamil; Khirsariya, Prashant; Souček, Karel; Krkoška, Martin; Blanářová, Olga Vondálová; Sova, Petr; Kozubík, Alois; Vaculová, Alena Hyršlová
Chk1 Inhibitor SCH900776 Effectively Potentiates the Cytotoxic Effects of Platinum-Based Chemotherapeutic Drugs in Human Colon Cancer Cells. Journal Article
In: Neoplasia (New York, N.Y.), vol. 19, no. 10, pp. 830–841, 2017, ISSN: 1476-5586 1522-8002, (Place: United States).
Abstract | Links | BibTeX | Tags: Antineoplastic Agents/*pharmacology, Apoptosis/drug effects, Cell Cycle/drug effects/genetics, Cell Line, Cell Survival/drug effects, Cellular Senescence/drug effects, Checkpoint Kinase 1/*antagonists & inhibitors/genetics/*metabolism, Cisplatin/pharmacology, Colonic Neoplasms/drug therapy/genetics/*metabolism/pathology, Cyclin-Dependent Kinase Inhibitor p21/genetics/metabolism, DNA Damage/drug effects, Gene Knockout Techniques, Humans, Platinum Compounds/*pharmacology, Pyrazoles/*pharmacology, Pyrimidines/*pharmacology, Tumor, Tumor Suppressor Protein p53/genetics/metabolism
@article{herudkova_chk1_2017,
title = {Chk1 Inhibitor SCH900776 Effectively Potentiates the Cytotoxic Effects of Platinum-Based Chemotherapeutic Drugs in Human Colon Cancer Cells.},
author = {Jarmila Herůdková and Kamil Paruch and Prashant Khirsariya and Karel Souček and Martin Krkoška and Olga Vondálová Blanářová and Petr Sova and Alois Kozubík and Alena Hyršlová Vaculová},
doi = {10.1016/j.neo.2017.08.002},
issn = {1476-5586 1522-8002},
year = {2017},
date = {2017-10-01},
journal = {Neoplasia (New York, N.Y.)},
volume = {19},
number = {10},
pages = {830–841},
abstract = {Although Chk1 kinase inhibitors are currently under clinical investigation as effective cancer cell sensitizers to the cytotoxic effects of numerous chemotherapeutics, there is still a considerable uncertainty regarding their role in modulation of anticancer potential of platinum-based drugs. Here we newly demonstrate the ability of one of the most specific Chk1 inhibitors, SCH900776 (MK-8776), to enhance human colon cancer cell sensitivity to the cytotoxic effects of platinum(II) cisplatin and platinum(IV)- LA-12 complexes. The combined treatment with SCH900776 and cisplatin or LA-12 results in apparent increase in G1/S phase-related apoptosis, stimulation of mitotic slippage, and senescence of HCT116 cells. We further show that the cancer cell response to the drug combinations is significantly affected by the p21, p53, and PTEN status. In contrast to their wt counterparts, the p53- or p21-deficient cells treated with SCH900776 and cisplatin or LA-12 enter mitosis and become polyploid, and the senescence phenotype is strongly suppressed. While the cell death induced by SCH900776 and cisplatin or LA-12 is significantly delayed in the absence of p53, the anticancer action of the drug combinations is significantly accelerated in p21-deficient cells, which is associated with stimulation of apoptosis beyond G2/M cell cycle phase. We also show that cooperative killing action of the drug combinations in HCT116 cells is facilitated in the absence of PTEN. Our results indicate that SCH900776 may act as an important modulator of cytotoxic response triggered by platinum-based drugs in colon cancer cells.},
note = {Place: United States},
keywords = {Antineoplastic Agents/*pharmacology, Apoptosis/drug effects, Cell Cycle/drug effects/genetics, Cell Line, Cell Survival/drug effects, Cellular Senescence/drug effects, Checkpoint Kinase 1/*antagonists & inhibitors/genetics/*metabolism, Cisplatin/pharmacology, Colonic Neoplasms/drug therapy/genetics/*metabolism/pathology, Cyclin-Dependent Kinase Inhibitor p21/genetics/metabolism, DNA Damage/drug effects, Gene Knockout Techniques, Humans, Platinum Compounds/*pharmacology, Pyrazoles/*pharmacology, Pyrimidines/*pharmacology, Tumor, Tumor Suppressor Protein p53/genetics/metabolism},
pubstate = {published},
tppubtype = {article}
}
Although Chk1 kinase inhibitors are currently under clinical investigation as effective cancer cell sensitizers to the cytotoxic effects of numerous chemotherapeutics, there is still a considerable uncertainty regarding their role in modulation of anticancer potential of platinum-based drugs. Here we newly demonstrate the ability of one of the most specific Chk1 inhibitors, SCH900776 (MK-8776), to enhance human colon cancer cell sensitivity to the cytotoxic effects of platinum(II) cisplatin and platinum(IV)- LA-12 complexes. The combined treatment with SCH900776 and cisplatin or LA-12 results in apparent increase in G1/S phase-related apoptosis, stimulation of mitotic slippage, and senescence of HCT116 cells. We further show that the cancer cell response to the drug combinations is significantly affected by the p21, p53, and PTEN status. In contrast to their wt counterparts, the p53- or p21-deficient cells treated with SCH900776 and cisplatin or LA-12 enter mitosis and become polyploid, and the senescence phenotype is strongly suppressed. While the cell death induced by SCH900776 and cisplatin or LA-12 is significantly delayed in the absence of p53, the anticancer action of the drug combinations is significantly accelerated in p21-deficient cells, which is associated with stimulation of apoptosis beyond G2/M cell cycle phase. We also show that cooperative killing action of the drug combinations in HCT116 cells is facilitated in the absence of PTEN. Our results indicate that SCH900776 may act as an important modulator of cytotoxic response triggered by platinum-based drugs in colon cancer cells.